window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

ALS

  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Al-S Pharma presents Phase 2 AP-101 data supporting misfolded SOD1 target in ALS at ENCALS 2026

    Al-S Pharma reports Phase 2 AP-101 data in ALS showing [...]

    June 25, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    PRISM ALS initiative develops patient-derived stem cell models to improve ALS/MND drug discovery

    A new global initiative aims to address long-standing limitations in [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    insitro and Bristol Myers Squibb expand ALS targets in AI collaboration

    insitro and Bristol Myers Squibb have expanded their ALS collaboration [...]

    May 5, 2026
  • Drug Discovery & Development,Therapeutic Areas

    Successful treatment for ALS could deliver billions in global value

    New research commissioned by Challenge Works and conducted by the [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    Medicinova wins contract research and development innovation award at biotech breakthrough awards 2025

    MediciNova has been recognised with the Contract Research and Development [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Leading global experts join judging panel for £7.5m Longitude Prize on ALS

    A panel of international leaders in neuroscience, artificial intelligence and [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics

    MaaT Pharma reports strong Phase 3 results and EMA submission for Xervyteg

    MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech focused on microbiome-based [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    NRG Therapeutics closes oversubscribed £50m series B to advance clinical data in Parkinson’s and proof of concept in ALS/MND

    NRG Therapeutics Ltd, a neuroscience company developing treatments targeting mitochondrial [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    MHRA approves Biogen’s tofersen for ultra-rare genetic form of motor neurone disease

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    AI-powered initiative in Louisiana aims to accelerate ALS drug discovery

    A new AI-led collaboration is being launched to advance drug [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top